Rheumatoid arthritis (RA)
Brittany Adler, MD
Johns Hopkins University
Baltimore, MD, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Namrata Singh, MD, MSc
University of Washington
Bellevue, WA, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Subclinical rheumatoid arthritis, in which patients have positive autoantibodies and/or subclinical synovitis that precedes clinical arthritis, is an increasingly common scenario in rheumatology practice. It is unclear how to manage these patients, and whether starting a DMARD can prevent the development of rheumatoid arthritis.
Therefore, we proposed a "Great Debate," in which two experts review the data on subclinical disease and the risk of progression to rheumatoid arthritis, and argue for or against starting a DMARD in this challenging clinical scenario.
Moderator: Brittany Adler, MD – Johns Hopkins University
Speaker: Kevin D. Deane, MD, PhD – University of Colorado Denver Anschutz Medical Campus
Speaker: V. Michael Holers, MD – University of Colorado
Speaker: Hani El-Gabalawy, MD, FRCPC – University of Manitoba
Speaker: Janet Pope, MD, FRCPC, MPH – University of Western Ontario
Speaker: V. Michael Holers, MD – University of Colorado
Speaker: Kevin D. Deane, MD, PhD – University of Colorado Denver Anschutz Medical Campus
Speaker: Janet Pope, MD, FRCPC, MPH – University of Western Ontario
Speaker: Hani El-Gabalawy, MD, FRCPC – University of Manitoba
